ArticleCancer science2018

Altered intracellular signaling by imatinib increases the anti-cancer effects of tyrosine kinase inhibitors in chronic myelogenous leukemia cells.

Takuya Hirao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.